On Invalid Date, Myriad Genetics (NASDAQ: MYGN) reported Q4 2022 earnings per share (EPS) of -$0.52, up 420% year over year. Total Myriad Genetics earnings for the quarter were -$42.30 million. In the same quarter last year, Myriad Genetics's earnings per share (EPS) was -$0.10.
As of Q1 2023, Myriad Genetics's earnings has grown year over year. Myriad Genetics's earnings in the past year totalled -$112.00 million.
What is MYGN's earnings date?
Myriad Genetics's earnings date is Invalid Date. Add MYGN to your watchlist to be reminded of MYGN's next earnings announcement.
What was MYGN's revenue last quarter?
On Invalid Date, Myriad Genetics (NASDAQ: MYGN) reported Q4 2022 revenue of $177.80 million up 10.57% year over year. In the same quarter last year, Myriad Genetics's revenue was $160.80 million.
What was MYGN's revenue growth in the past year?
As of Q1 2023, Myriad Genetics's revenue has grown -1.77% year over year. This is 12.4 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 10.63%. Myriad Genetics's revenue in the past year totalled $678.40 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.